1.張玉玲,，蔡均均，韓濤,，周靜.化膿性肝膿腫伴發(fā)急性腎損傷的危險(xiǎn)因素分析.山東醫(yī)藥,，2016,56(8):49-51.
2.龔艷清，韓濤,，章坤,，張倩.長(zhǎng)鏈非編碼RNA在肝癌中的研究進(jìn)展.山東醫(yī)藥，2016,56(10):96-98.
3.周冷瀟,，韓濤. HBV和HCV母嬰阻斷的研究進(jìn)展.臨床肝膽病雜志,，2016,32(6):14-18.
4.Yong Jiang, Zhi-Guang Zhang, Feng-Xiang Qi, Ying Zhang, Tao Han. Comparison of Maintenance Effect of Probiotics and Aminosalicylates on Ulcerative Colitis:A Meta-analysis of Randomized Controlled Trials. Chronic Diseases and Translational Medicine. 2016
5.Kun Zhang, Yanan Chang, Zhemin Shi, Xiaohui Han, Yawei Han, QingbinYao, Zhimei Hu, Hongmei Cui, Lina Zheng, Tao Han, Wei Hong. ω-3 PUFAs Ameliorate Liver Fibrosis and Inhibit Hepatic Stellate Cells Proliferation and Activation by Promoting YAP/TAZ Degradation.Scientific Reports. 2016,6:30029.
6.尹偉利，韓濤. ART Score and Hepatocellular Carcinoma: An appraisal of its applicability.. Clin Res Hepatol Gastroenterol, 2016 Dec;40(6):705-714.
7.葉青,，韓濤. Association between the HFE C282Y, H63D Polymorphisms and the Risks of Non-Alcoholic Fatty Liver Disease,Liver Cirrhosis and Hepatocellular Carcinoma: An Updated Systematic Review and Meta-Analysis of 5,758 Cases and 14,741 Controls. PLoS One, 2016,11(9):e0163423.
8.葉青,韓濤.肝硬化患者營(yíng)養(yǎng)不良狀態(tài)和體成分分析.中華肝臟病, 2016年5月第24卷第5期：380-383.
9.梁靜,向慧玲. Short-term Clinical Evaluation of Recombinant Humanthrombopoietin Treating on Thrombocytopaenia in Patients
with Liver Cirrhosisassociated with Viral Hepatitis. Int J Clin Exp Med, Int J Clin Exp Med 2016;9(11):22148-22154.
10.新技術(shù)：李雋,組織膠聚桂醇單次多點(diǎn)注射內(nèi)鏡根治門(mén)脈高壓胃靜脈曲張獲2015年天津市衛(wèi)生系統(tǒng)引進(jìn)應(yīng)用新技術(shù)填補(bǔ)空白項(xiàng)目(2015.12).
11.專(zhuān)利：肖國(guó)卿,，一種一次性使用肌電圖誘發(fā)電位儀用單極針.
(消化(肝病)科)
|
